Obstructive Sleep Apnea Syndrome. Effects of Therapy on Dyslipidemia

Summary Objective Dyslipidemia is frequently observed in patients with obstructive sleep apnea syndrome (OSAS). The effects of OSAS treatment on lipid levels in these patients have been examined. Patients and Methods 95 consecutive patients (aged 56.6±9.5 years) with polysomnographically verified OSAS and LDL cholesterol levels of more than 130 mg per deciliter have been included in a prospective trial. Plasma total cholesterol, high‐density lipoprotein (HDL) cholesterol, low‐density lipoprotein (LDL) cholesterol, triglyceride, apolipoprotein B, and lipoprotein (a) levels were determined in all patients at baseline and after long term therapy. Results Total cholesterol (249.9 ± 31.4 vs. 240.0 ± 34.1 mg/dL; p = 0.01) and LDL cholesterol levels (179.4 ± 29.4 vs. 165.5 ± 32.5 mg/dL; p 130 mg/dl wurden in die vorliegende Studie aufgenommen. Bei allen Patienten wurden zum Ausgangszeitpunkt und nach einer OSAS‐Langzeittherapie Gesamtcholesterin, high‐density lipoprotein (HDL) Cholesterin, low‐density lipoprotein (LDL) Cholesterin, Triglyzeride, Apolipoprotein B sowei Lipoprotein (a) bestimmt. Ergebnisse Das Gesamtcholesterin (249,9 ± 31,4 vs. 240,0 ± 34,1 mg/dl; p = 0,01) sowie das LDL‐Cholesterin (179,4 ± 29,4 vs. 165,5 ± 32,5 mg/dl; p